Bob Stoll, partner and co-chair of the intellectual property group in Washington, D.C., was quoted in a recent STAT article titled “The Power of a Patent: Will a New Trump Appointee Chip Away at Pharma’s Monopolies?” The article explores whether Andrei Iancu, the new director of the U.S. Patent and Trademark Office, will work to rein in drug companies or deliver on their wish lists. In his new role, Iancu has the power to rein in drug makers through his sway over the intellectual property system. However, Iancu’s list of priorities with respect to pharmaceutical companies has been unclear in the three weeks since he took office.
Bob said, “Iancu is just getting into position. But I think he’s very steeped in patent issues. … He knows where the pressure points are in the patent system. He’s well aware of what the patent community is thinking about.”